Shenouda Maged's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed Sep 11, 2026
- Accession no.
- 0001213900-26-098970
- Filed
- Sep 11, 2026, 7:30 AM ET
- Trade date
- Sep 9-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $844.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shenouda MagedCIK 0001658369 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Common Stock | PPurchaseAcquired | +120,200 | $4.20F2 | +$504,840 | 920,200 | Direct | |
| Sep 10, 2026 | Common Stock | PPurchaseAcquired | +79,800 | $4.25 | +$339,150 | 1,000,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $4.16 to $4.20 per share, inclusive.
Referenced by the price of 1 transaction in Table I.